Zucker kann leuchten wie eine Seifenblase – CMCB-Technologieplattform unterstützt Mikroskopie-Kurse für Kinder im neu eingeweihten digitalen Klassenzimmer
Prof. Michael Schlierf ist neuer Institutsdirektor des B CUBE
Anton Batalov, PicoQuant
Dr. Kerstin Blank, MPI Potsdam-Golm
High-Tech Gründerfonds and Technologiegründerfonds Sachsen support enabling human biology in vitro with an investment in the B CUBE spin-off denovoMATRIX
denovoMATRIX develops and manufactures biomimetic coatings for stem cell culture. With its technology, the team of denovoMATRIX enables cutting edge research in the stem cell field, and aims to revolutionize cell culture processes in Life Science research. The HTGF together with TGFS are participating in the seed financing round to support the growing denovoMATRIX team, and the launch of denovoMATRIX products into the market.
In recent months, denovoMATRIX has received great feedback and support from industry experts, winning the Innovation prize from IQ-Mitteldeutschland Life Science Cluster. ‘’Although we are pleased with our performance at various businessplan competitions, we are currently focusing our attention on our myMATRIX product line, designed for streamlining cell culture processes using defined, serum-free conditions’’ explains the CEO of denovoMATRIX, Dejan Husman. The start-up already has their first product line – the screenMATRIX – available for purchase through their website. It is a tool designed for researchers interested in discovering the ideal conditions for culturing their cells.
Dr. Fabian Mohr, Investment Manager at HTGF: "In order to be able to offer high-quality stem cell therapies in the future, manufacturers must keep their variability in cell cultivation low. denovoMATRIX products offer a chemically defined solution to this problem, which we hope will provide a good basis for the translation of stem cell therapies from research into clinical practice.
In August 2018, denovoMATRIX GmbH was founded as a spin-off of the Technische Universität Dresden. With the support of the Bundesministerium für Wirtschaft und Energie (BMWi) funding program EXIST Transfer of Research, the founders were able to commercialize the technology developed at the B CUBE – Center for Molecular Bioengineering. The vision of denovoMATRIX is to enable human biology in vitro – a broad mission to foster research in cell culture, and accelerate the implementation of cell-based therapies for the treatment of diseases.